Navigation Links
New therapeutic strategy could target toxic protein in most patients with Huntington's disease
Date:4/9/2009

Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons. Laboratory studies suggest that a single small interfering RNA could reduce production of the damaging Huntingtin protein in nearly half of people with the disease. Another 25 percent of patients might benefit from one of a set of four additional small interfering RNAs.

Phillip D. Zamore, an HHMI investigator at the University of Massachusetts Medical School in Worcester, and his colleagues reported their findings in an article published April 9, 2009, in the journal Current Biology.

There is no treatment for Huntington's disease, which is caused by a mutant form of the Huntingtin gene. Huntingtin is required for healthy nerve cells, but the mutant gene makes a toxic protein that contains excess amounts of the amino acid glutamine.

The key to whether the Huntingtin gene is normal or defective lies in a kind of genetic stutter: a repetitive sequence of the DNA triplet CAG, which codes for the amino acid glutamine. Stretches of CAG "repeats" appear in every human being's Huntingtin gene, but the length varies. Whereas the normal gene has a sequence of between six and 34 CAG repeats, the abnormal gene contains many more. In fact, any stretch of DNA containing more than 40 of these repeats ensures that its bearer will develop Huntington'sthe greater the number of repeats, the earlier the disease strikes and the greater its ferocity. The abnormal Huntingtin protein causes movement disorders, cognitive failure, and ultimately, death. Children who have a parent with Huntington's disease have a 50 percent chance of inheriting the disease themselves.

Zamore studies how RNA interference can be used to silence genes selectively. In the 1990s, he and other scientists lea
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Using evolution, UW team creates a template for many new therapeutic agents
2. The endocannabinoids: Functional roles and therapeutic opportunities
3. Potential new therapeutic molecular target to fight cancer
4. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
5. Methadone even at therapeutic levels can kill
6. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
7. Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find
8. New technology enhances therapeutic potential of cord blood stem cells
9. Novel therapeutic strategy for colon cancer treatment
10. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
11. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...RSA (methicillin-resistant Staphylococcus Aureus ...ihilation as low-temperature plasma prototype devi... and unfailing bactericidal cocktails. , Two pro...ent disinfection of healthy skin (e.g. hands and f... can pose a lethal threat; and another to shoot ba...
(Date:11/25/2009)...thens, Ga. Bacteria don,t have easy lives. In add... bugs, they have natural enemies called bacterioph... every two days. , Still, bacteria and another ...overed in extreme environments such as deep-sea vo... because they have a built-in defense system that ...
(Date:11/25/2009)...ADISON, WI, NOVEMBER 25, 2009 Soil is the linchpi... and hydrosphere meet. Despite that, many students...but nothing more. Soil science educators are chall...blic recognize the critical importance of soil in ...oil science and earth science teachers at Universi...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Now butterflies are also being counted in China Australia and Israel 9574 1Now butterflies are also being counted in China Australia and Israel 9574 2Now butterflies are also being counted in China Australia and Israel 9574 3Now butterflies are also being counted in China Australia and Israel 9574 4International Robotic Surgery Forum Launches In Chicago 54545 1International Robotic Surgery Forum Launches In Chicago 54545 2International Robotic Surgery Forum Launches In Chicago 54545 3Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 1Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 2Biopelle Inc Acquires PRESCRIBEDsolutions 5BCUSTOMIZED SKINCARE 5D 28R 29 54541 3
...y of Pennsylvania researchers have uncovered an im...ses cooperating proteins found on its outer coat t...Further, the studys authors say, they have demonst...n interactions using biomolecular complementation....the National Academy of Sciences, provide a better...
...ong been a staple for people planning their day. N...re working to broaden daily forecasts to include p... reality in some parts of the world. , Some scien...e, global forecasts of air pollution near the grou...ears away. Such a system could prove useful in eff...
...tural climate variations, which tend to involve lo...ve a larger effect on hurricane activity than the ...in this week,s Nature suggests. , In the debate o... is generally assumed that warmer oceans provide a...ent and intensification. However, several other fa...
Other Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Air quality forecasts see future in space 2Air quality forecasts see future in space 3Climate's remote control on hurricanes 2
(Date:11/24/2009)... , , Primary efficacy endpoint has been me...t endometrial cancer, , QUEBEC CITY, Nov. 24 ...SDAQ: AEZS ; TSX: AEZ) (the "Company"), a global ...rapy and oncology, today announced positive effica...otoxic peptide conjugate, AEZS-108 (formerly AN-15...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-FirstC... global specialty biopharmaceutical company, today...pean Medicines Agency for,velaglucerase alfa, the ...t,for the treatment of Type 1 Gaucher disease. Thi...rase alfa that has been submitted, with previous,s...
(Date:11/24/2009)... , REDWOOD CITY, Calif., Nov. 24 /PRNewswire... ) today announced that Randy Scott, Genomic Healt...nnual Piper Jaffray Health Care Conference in New ...m. ET. ,, To access the live and subsequently ...vestor Relations section of Genomic Health,s websi...
(Date:11/24/2009)... Program Connects Customers wi...es Collected with DNA Genotek Products , ...09 -- DNA Genotek , a leading provider of product...and preparation, today announced its new global pa...ncements for DNA Genotek,s partner community and i...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
... DuPont Applied BioSciences has turned to MB...ing the commercial viability of an important bio-b...n bridging the gap between research and commercial...sed technologies. MBI’s unique “Collab...ddresses technological uncertainties, which impede...
...ec. 2 GeneGo, Inc., the leading systems biology t...ome a certified GeneGo Center of Excellence. Burnh...o GeneGo,s MetaCore data analysis suite, training ...world-class biomedical research facility running m... departments, including research in cancer, stem c...
...ec. 2 Intradigm Corporation, a leading,developer ...apeutics, today,announced the issuance of United S...ositions for Controlling Efficacy of RNA Silencing...al research of Philip Zamore, Ph.D., the,Gretchen ...sor of Biochemistry,& Molecular Pharmacology a...
Other Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3
Human HGF, Unconjugated from R&D Systems
Bovine PC-BSA (Bovine Serum Albumin), Unconjugated from Biosearch Technologies
Ral Immunoblot Assay Kit from Upstate
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)
Biology Products: